JAZZ is expected to report earnings to fall 2.52% to $6.18 per share on August 05
Q2'26
Est.
$6.18
Q1'26
Beat
by $1.72
Q4'25
Beat
by $0.25
Q3'25
Beat
by $2.20
Q2'25
Missed
by $0.63
The last earnings report on May 05 showed earnings per share of $6.34, beating the estimate of $4.62. With 860.94K shares outstanding, the current market capitalization sits at 14.47B.
A.I. Advisor
published General Information
General Information
a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products
A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with ZYME. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then ZYME could also see price increases.
The 10-day RSI Oscillator for JAZZ moved out of overbought territory on May 28, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JAZZ as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for JAZZ turned negative on May 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 174 cases where JAZZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAZZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.131) is normal, around the industry mean (20.966). JAZZ's P/E Ratio (2053.818) is considerably higher than the industry average of (36.007). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (1.690). JAZZ has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (3.169) is also within normal values, averaging (367.026).
Jazz Pharmaceuticals (JAZZ) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com
